Fate Therapeutics Company

Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.
Technology: mHealth
Industry: Genomic and Epigenominc Instabillity
Headquarters: United States
Founded Date: 2007
Employees Number: 11-50
Funding Status: IPO
Investors Number: 7
Total Funding: $360.2M
Estimated Revenue: $1M to $10M
Last Funding Type: Post-IPO Equity

Visit Website
Register and Claim Ownership